vs
因美纳（ILMN）与帕可Bio（PACB）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是帕可Bio的24.7倍（$1.1B vs $44.6M）。因美纳净利率更高（16.8% vs -90.4%，领先107.3%）。帕可Bio同比增速更快（13.8% vs -1.6%）。因美纳自由现金流更多（$335.0M vs $-19.9M）。过去两年帕可Bio的营收复合增速更高（7.3% vs 0.8%）
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
ILMN vs PACB — 直观对比
营收规模更大
ILMN
是对方的24.7倍
$44.6M
营收增速更快
PACB
高出15.4%
-1.6%
净利率更高
ILMN
高出107.3%
-90.4%
自由现金流更多
ILMN
多$354.9M
$-19.9M
两年增速更快
PACB
近两年复合增速
0.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $44.6M |
| 净利润 | $186.0M | $-40.4M |
| 毛利率 | 65.9% | 37.1% |
| 营业利润率 | 15.8% | -92.3% |
| 净利率 | 16.8% | -90.4% |
| 营收同比 | -1.6% | 13.8% |
| 净利润同比 | 205.7% | -1802.7% |
| 每股收益（稀释后） | $1.16 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ILMNPACB
| Q4 25 | — | $44.6M | ||
| Q3 25 | — | $38.4M | ||
| Q2 25 | — | $39.8M | ||
| Q1 25 | — | $37.2M | ||
| Q4 24 | $1.1B | $39.2M | ||
| Q3 24 | $1.1B | $40.0M | ||
| Q2 24 | $1.1B | $36.0M | ||
| Q1 24 | $1.1B | $38.8M |
净利润ILMNPACB
| Q4 25 | — | $-40.4M | ||
| Q3 25 | — | $-38.0M | ||
| Q2 25 | — | $-41.9M | ||
| Q1 25 | — | $-426.1M | ||
| Q4 24 | $186.0M | $2.4M | ||
| Q3 24 | $705.0M | $-60.7M | ||
| Q2 24 | $-2.0B | $-173.3M | ||
| Q1 24 | $-126.0M | $-78.2M |
毛利率ILMNPACB
| Q4 25 | — | 37.1% | ||
| Q3 25 | — | 41.4% | ||
| Q2 25 | — | 36.9% | ||
| Q1 25 | — | -3.7% | ||
| Q4 24 | 65.9% | 25.6% | ||
| Q3 24 | 69.0% | 25.0% | ||
| Q2 24 | 64.8% | 16.5% | ||
| Q1 24 | 62.0% | 29.1% |
营业利润率ILMNPACB
| Q4 25 | — | -92.3% | ||
| Q3 25 | — | -101.1% | ||
| Q2 25 | — | -112.8% | ||
| Q1 25 | — | -1154.5% | ||
| Q4 24 | 15.8% | -390.1% | ||
| Q3 24 | 68.6% | -160.3% | ||
| Q2 24 | -147.2% | -488.3% | ||
| Q1 24 | -10.3% | -209.6% |
净利率ILMNPACB
| Q4 25 | — | -90.4% | ||
| Q3 25 | — | -98.9% | ||
| Q2 25 | — | -105.4% | ||
| Q1 25 | — | -1146.8% | ||
| Q4 24 | 16.8% | 6.0% | ||
| Q3 24 | 65.3% | -151.9% | ||
| Q2 24 | -178.8% | -481.3% | ||
| Q1 24 | -11.7% | -201.4% |
每股收益（稀释后）ILMNPACB
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $-0.13 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-1.44 | ||
| Q4 24 | $1.16 | $-0.44 | ||
| Q3 24 | $4.42 | $-0.22 | ||
| Q2 24 | $-12.48 | $-0.64 | ||
| Q1 24 | $-0.79 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.0M | $279.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $5.3M |
| 总资产 | $6.3B | $784.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ILMNPACB
| Q4 25 | — | $279.5M | ||
| Q3 25 | — | $298.7M | ||
| Q2 25 | — | $314.7M | ||
| Q1 25 | — | $343.1M | ||
| Q4 24 | $93.0M | $389.9M | ||
| Q3 24 | $70.0M | $471.1M | ||
| Q2 24 | $74.0M | $509.8M | ||
| Q1 24 | — | $561.9M |
股东权益ILMNPACB
| Q4 25 | — | $5.3M | ||
| Q3 25 | — | $36.1M | ||
| Q2 25 | — | $61.5M | ||
| Q1 25 | — | $91.6M | ||
| Q4 24 | $2.4B | $506.6M | ||
| Q3 24 | $2.1B | $453.1M | ||
| Q2 24 | $1.4B | $492.7M | ||
| Q1 24 | $5.7B | $649.0M |
总资产ILMNPACB
| Q4 25 | — | $784.1M | ||
| Q3 25 | — | $803.2M | ||
| Q2 25 | — | $825.5M | ||
| Q1 25 | — | $860.8M | ||
| Q4 24 | $6.3B | $1.3B | ||
| Q3 24 | $6.0B | $1.5B | ||
| Q2 24 | $6.1B | $1.5B | ||
| Q1 24 | $10.0B | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $364.0M | $-19.1M |
| 自由现金流经营现金流 - 资本支出 | $335.0M | $-19.9M |
| 自由现金流率自由现金流/营收 | 30.3% | -44.6% |
| 资本支出强度资本支出/营收 | 2.6% | 1.9% |
| 现金转化率经营现金流/净利润 | 1.96× | — |
| 过去12个月自由现金流最近4个季度 | $709.0M | $-114.1M |
8季度趋势，按日历期对齐
经营现金流ILMNPACB
| Q4 25 | — | $-19.1M | ||
| Q3 25 | — | $-18.7M | ||
| Q2 25 | — | $-29.4M | ||
| Q1 25 | — | $-44.1M | ||
| Q4 24 | $364.0M | $-30.6M | ||
| Q3 24 | $316.0M | $-45.5M | ||
| Q2 24 | $80.0M | $-54.3M | ||
| Q1 24 | $77.0M | $-75.7M |
自由现金流ILMNPACB
| Q4 25 | — | $-19.9M | ||
| Q3 25 | — | $-18.8M | ||
| Q2 25 | — | $-29.9M | ||
| Q1 25 | — | $-45.4M | ||
| Q4 24 | $335.0M | $-32.3M | ||
| Q3 24 | $284.0M | $-46.3M | ||
| Q2 24 | $49.0M | $-55.7M | ||
| Q1 24 | $41.0M | $-79.6M |
自由现金流率ILMNPACB
| Q4 25 | — | -44.6% | ||
| Q3 25 | — | -48.9% | ||
| Q2 25 | — | -75.3% | ||
| Q1 25 | — | -122.3% | ||
| Q4 24 | 30.3% | -82.3% | ||
| Q3 24 | 26.3% | -115.7% | ||
| Q2 24 | 4.4% | -154.8% | ||
| Q1 24 | 3.8% | -205.0% |
资本支出强度ILMNPACB
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | 2.6% | 4.1% | ||
| Q3 24 | 3.0% | 2.0% | ||
| Q2 24 | 2.8% | 4.1% | ||
| Q1 24 | 3.3% | 10.0% |
现金转化率ILMNPACB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.96× | -12.93× | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ILMN
| Sequencing | $1.0B | 91% |
| Microarray | $101.0M | 9% |
| Investee | $7.0M | 1% |
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
